Your browser doesn't support javascript.
loading
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.
Overbeek, J K; Ter Heine, R; Verheul, H M W; Chatelut, E; Rudek, M A; Gurney, H; Plummer, R; Gilbert, D C; Buclin, T; Burger, D M; Bloemendal, H J; van Erp, N P.
Afiliação
  • Overbeek JK; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Ter Heine R; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Verheul HMW; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen; Department of Medical Oncology, Erasmus University MC Cancer Institute, Rotterdam, Netherlands.
  • Chatelut E; Institut Claudius-Regaud, IUCT-Oncopole, and CRCT, Université de Toulouse, Inserm, 1, Toulouse, France; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore.
  • Rudek MA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore; Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, USA.
  • Gurney H; Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Macquarie Park, Australia.
  • Plummer R; Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne.
  • Gilbert DC; MRC Clinical Trials Unit, University College London (UCL), Institute of Clinical Trials and Methodology, London, UK; Optimal Cancer Care Alliance, Ann Arbor, USA.
  • Buclin T; Division of Clinical Pharmacology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Burger DM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Bloemendal HJ; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen.
  • van Erp NP; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands. Electronic address: Nielka.vanErp@radboudumc.nl.
ESMO Open ; 8(1): 100749, 2023 02.
Article em En | MEDLINE | ID: mdl-36603522
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Uso Off-Label / Antineoplásicos Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Uso Off-Label / Antineoplásicos Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda